Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-postive Metastatic Breast Cancer.
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet therapy immediately following T-DXd therapy in patients diagnosed with HER2+ metastatic breast cancer (mBC) in the United States.
Metastatic HER2+ Advanced Breast Cancer
DRUG: Tucatinib|DRUG: Trastuzumab|DRUG: Capecitabine
Time to Next Treatment, Time to next treatment defined as the time in months from the initiation of therapy to the initiation of subsequent LOT or death., 1 Year|Time to Discontinuation, Time to treatment discontinuation defined as the time in months from initiation of therapy to discontinuation for any reason or death., 1 Year|Overall survival (OS), OS will be defined as the time in months from initiation of therapy to death from any cause., 1 Year
A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Database to describe 3L and 4L real-world (rw) outcomes (e.g. time to next treatment, time to discontinuation, and overal survival) of the tucatinib-trastuzumab-capecitabine triplet therapy immediately following T-DXd therapy in patients diagnosed with HER2+ metastatic breast cancer (mBC) in the United States.